WuXi Biologics acquires first EU drug product facility through Bayer deal
WuXi Biologics has continued its rapid development through further extension of its European footprint by agreeing an acquisition deal for one of Bayer’s facilities.
The Leverkusen, Germany, located facility currently produces Kovaltry (antihemophilic factor (recombinant)). Once the acquisition completes, which is expected in the ‘coming months’, WuXi Biologics will become a backup manufacturer for the treatment.
Bayer will remain the principal manufacturer of the product through its California-based drug substance and drug product facility.
In addition to the facility, WuXi Biologics will also acquire all of the associated equipment held in the facility, as well as picking up the long-term lease contract for the building.
CEO of WuXi Biologics, Chris Chen, noted that the company will continue to expand its worldwide capacity, in light of “robust growth” experience in EU, US and Chinese markets.
The contract development and manufacturing organization (CDMO) is already constructing a manufacturing facility in Ireland, which will hold the largest single-use capabilities in the country.
Beyond this, the Chinese company has received European Medicine Agency good manufacturing practice (GMP) certification to produce Trogarzo (ibalizumab) for the European market.